## Sylvain Lehmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/534767/publications.pdf

Version: 2024-02-01

268 papers

13,645 citations

18482 62 h-index 27406 106 g-index

299 all docs 299 docs citations

times ranked

299

14104 citing authors

#	Article	IF	CITATIONS
1	Signal Transduction Through Prion Protein. Science, 2000, 289, 1925-1928.	12.6	701
2	Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrPC, in Cultured Cells. Journal of Biological Chemistry, 1995, 270, 30221-30229.	3.4	538
3	Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes and Development, 2011, 25, 2248-2253.	5.9	444
4	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nature Medicine, 2020, 26, 398-407.	30.7	351
5	Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease. Alzheimer's Research and Therapy, 2019, 11, 34.	6.2	325
6	Cell specific differences between human adipose-derived and mesenchymal–stromal cells despite similar differentiation potentials. Experimental Cell Research, 2008, 314, 1575-1584.	2.6	316
7	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomarkers in Medicine, 2012, 6, 419-430.	1.4	280
8	Screening of 145 Anti-PrP Monoclonal Antibodies for Their Capacity to Inhibit PrPSc Replication in Infected Cells. Journal of Biological Chemistry, 2005, 280, 11247-11258.	3.4	272
9	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	3.0	249
10	Successful Transmission of Three Mouse-Adapted Scrapie Strains to Murine Neuroblastoma Cell Lines Overexpressing Wild-Type Mouse Prion Protein. Journal of Virology, 2000, 74, 320-325.	3.4	220
11	Prion infection impairs the cellular response to oxidative stress. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 13937-13942.	7.1	203
12	Ex vivo propagation of infectious sheep scrapie agent in heterologous epithelial cells expressing ovine prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 4055-4059.	7.1	203
13	Expression of Prion Protein Increases Cellular Copper Binding and Antioxidant Enzyme Activities but Not Copper Delivery. Journal of Biological Chemistry, 2003, 278, 9064-9072.	3.4	173
14	Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. Journal of General Virology, 2004, 85, 1791-1799.	2.9	172
15	Oxidative stress and the prion protein in transmissible spongiform encephalopathies. Brain Research Reviews, 2002, 38, 328-339.	9.0	167
16	Standard Preanalytical Coding for Biospecimens: Defining the Sample PREanalytical Code. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1004-1011.	2.5	166
17	Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival. Molecular and Cellular Neurosciences, 2003, 22, 227-233.	2.2	164
18	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet, The, 2020, 395, 1988-1997.	13.7	164

#	Article	IF	CITATIONS
19	Blockade of Glycosylation Promotes Acquistion of Scrapie-like Properties by the Prion Protein in Cultured Cells. Journal of Biological Chemistry, 1997, 272, 21479-21487.	3.4	163
20	Important research questions in allergy and related diseases: nonallergic rhinitis: a GA <sup>2</sup> LEN paper. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 842-853.	5.7	158
21	Cleavage of the Amino Terminus of the Prion Protein by Reactive Oxygen Species. Journal of Biological Chemistry, 2001, 276, 2286-2291.	3.4	154
22	Alpha- and beta- cleavages of the amino-terminus of the cellular prion protein. Biology of the Cell, 2004, 96, 125-132.	2.0	150
23	Evidence for a Six-transmembrane Domain Structure of Presenilin 1. Journal of Biological Chemistry, 1997, 272, 12047-12051.	3.4	143
24	A Mutant Prion Protein Displays an Aberrant Membrane Association When Expressed in Cultured Cells. Journal of Biological Chemistry, 1995, 270, 24589-24597.	3.4	141
25	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet Neurology, The, 2018, 17, 860-869.	10.2	140
26	Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2008, 67, 741-749.	0.9	139
27	Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. Alzheimer's Research and Therapy, 2020, 12, 26.	6.2	138
28	Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1251-1261.	3.0	131
29	Mutant and Infectious Prion Proteins Display Common Biochemical Properties in Cultured Cells. Journal of Biological Chemistry, 1996, 271, 1633-1637.	3.4	128
30	Filipin Prevents Pathological Prion Protein Accumulation by Reducing Endocytosis and Inducing Cellular PrP Release. Journal of Biological Chemistry, 2002, 277, 25457-25464.	3.4	126
31	Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles. Biology of the Cell, 2008, 100, 603-618.	2.0	124
32	Amphotericin B Inhibits the Generation of the Scrapie Isoform of the Prion Protein in Infected Cultures. Journal of Virology, 2000, 74, 3135-3140.	3.4	112
33	Retrovirus infection strongly enhances scrapie infectivity release in cell culture. EMBO Journal, 2006, 25, 2674-2685.	7.8	112
34	Anti-PrP antibodies block PrPScreplication in prion-infected cell cultures by accelerating PrPCdegradation. Journal of Neurochemistry, 2004, 89, 454-463.	3.9	111
35	Metal ions and prion diseases. Current Opinion in Chemical Biology, 2002, 6, 187-192.	6.1	105
36	Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2016, 51, 1033-1043.	2.6	104

3

#	Article	IF	CITATIONS
37	Human Biospecimen Research: Experimental Protocol and Quality Control Tools. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1017-1025.	2.5	103
38	Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers. Alzheimer's and Dementia, 2018, 14, 858-868.	0.8	103
39	Current and future use of "dried blood spot―analyses in clinical chemistry. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1897-1909.	2.3	102
40	Cerebrospinal fluid amyloid- $\hat{l}^2$ 42/40 ratio in clinical setting of memory centers: a multicentric study. Alzheimer's Research and Therapy, 2015, 7, 30.	6.2	101
41	Two mutant prion proteins expressed in cultured cells acquire biochemical properties reminiscent of the scrapie isoform Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 5610-5614.	7.1	98
42	Phorbol Ester-regulated Cleavage of Normal Prion Protein in HEK293 Human Cells and Murine Neurons. Journal of Biological Chemistry, 2000, 275, 35612-35616.	3.4	98
43	Stimulation of PrPC Retrograde Transport toward the Endoplasmic Reticulum Increases Accumulation of PrPSc in Prion-infected Cells. Journal of Biological Chemistry, 2002, 277, 38972-38977.	3.4	98
44	Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes. Journal of Alzheimer's Disease, 2012, 31, 13-20.	2.6	94
45	Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity. Journal of Proteome Research, 2016, 15, 667-676.	3.7	91
46	Depletion of one, six, twelve or twenty major blood proteins before proteomic analysis: The more the better?. Journal of Proteomics, 2009, 72, 945-951.	2.4	89
47	Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers. Proteomics - Clinical Applications, 2008, 2, 428-436.	1.6	88
48	Operational definition of Active and Healthy Ageing (AHA): A conceptual framework. Journal of Nutrition, Health and Aging, 2015, 19, 955-960.	3.3	85
49	Identification of Intermediate Steps in the Conversion of a Mutant Prion Protein to a Scrapie-like Form in Cultured Cells. Journal of Biological Chemistry, 1997, 272, 11604-11612.	3.4	84
50	Comparative proteomic analysis of human mesenchymal and embryonic stem cells: Towards the definition of a mesenchymal stem cell proteomic signature. Proteomics, 2009, 9, 223-232.	2.2	82
51	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.8	82
52	PrP-dependent cell adhesion in N2a neuroblastoma cells. FEBS Letters, 2002, 514, 159-162.	2.8	81
53	Scrapie-like prion protein is translocated to the nuclei of infected cells independently of proteasome inhibition and interacts with chromatin. Journal of Cell Science, 2004, 117, 2411-2416.	2.0	78
54	Prion propagation in cultured cells. British Medical Bulletin, 2003, 66, 87-97.	6.9	77

#	Article	IF	CITATIONS
55	Trehalose impairs aggregation of PrPSc molecules and protects prion-infected cells against oxidative damage. Biochemical and Biophysical Research Communications, 2008, 374, 44-48.	2.1	76
56	Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. Neurobiology of Aging, 2017, 53, 59-66.	3.1	76
57	The Human "Prion-like―Protein Doppel Is Expressed in Both Sertoli Cells and Spermatozoa. Journal of Biological Chemistry, 2002, 277, 43071-43078.	3.4	75
58	PrP Expression and Replication by Schwann Cells: Implications in Prion Spreading. Journal of Virology, 2002, 76, 2434-2439.	3.4	72
59	Neuropathology of iatrogenic Creutzfeldt–Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of Abeta pathology. Acta Neuropathologica, 2018, 135, 201-212.	7.7	71
60	Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. Leukemia, 2015, 29, 1084-1091.	7.2	70
61	Correlations between soluble $\hat{l}\pm /\hat{l}^2$ forms of amyloid precursor protein and $\hat{Al}^2$ 38, 40, and 42 in human cerebrospinal fluid. Brain Research, 2010, 1357, 175-183.	2.2	69
62	Decreased $sA\hat{l}^2PP\hat{l}^2$ , $A\hat{l}^238$ , and $A\hat{l}^240$ Cerebrospinal Fluid Levels in Frontotemporal Dementia. Journal of Alzheimer's Disease, 2011, 26, 553-563.	2.6	65
63	Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria. Journal of Neurology, 2012, 259, 2429-2433.	3 <b>.</b> 6	65
64	Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimer's and Dementia, 2013, 9, 406-413.	0.8	63
65	Systems Medicine Approaches for the Definition of Complex Phenotypes in Chronic Diseases and Ageing. From Concept to Implementation and Policies. Current Pharmaceutical Design, 2014, 20, 5928-5944.	1.9	63
66	The scrapie prion protein is present in flotillin-1-positive vesicles in central- but not peripheral-derived neuronal cell lines. European Journal of Neuroscience, 2005, 21, 2063-2072.	2.6	62
67	Relevance of A $\hat{1}^2$ 42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. Frontiers in Aging Neuroscience, 2018, 10, 138.	3.4	59
68	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis., 2014, 10, S390-S394.e2.		58
69	Prion Infection Impairs Copper Binding of Cultured Cells. Journal of Biological Chemistry, 2003, 278, 14595-14598.	3.4	54
70	Brain and buffy coat transmission of bovine spongiform encephalopathy to the primate Microcebus murinus. Transfusion, 2002, 42, 513-516.	1.6	52
71	Impact of the 2008–2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study. Journal of Alzheimer's Disease, 2013, 34, 297-305.	2.6	51
72	Cerebrospinal Fluid Collection Tubes: A Critical Issue for Alzheimer Disease Diagnosis. Clinical Chemistry, 2012, 58, 787-789.	3.2	50

#	Article	IF	Citations
73	Prion protein protects against DNA damage induced by paraquat in cultured cells. Free Radical Biology and Medicine, 2004, 37, 1224-1230.	2.9	47
74	Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application. Clinical Chemistry and Laboratory Medicine, 2013, 51, 919-35.	2.3	47
75	Efficient inhibition of infectious prions multiplication and release by targeting the exosomal pathway. Cellular and Molecular Life Sciences, 2015, 72, 4409-4427.	5.4	47
76	An endogenous lectin and one of its neuronal glycoprotein ligands are involved in contact guidance of neuron migration Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 6455-6459.	7.1	46
77	X-linked adrenal hypoplasia congenita is caused by abnormal nuclear localization of the DAX-1 protein. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8225-8230.	7.1	46
78	Prion strains are differentially released through the exosomal pathway. Cellular and Molecular Life Sciences, 2015, 72, 1185-1196.	5 <b>.</b> 4	46
79	Developmental determinants in non-communicable chronic diseases and ageing. Thorax, 2015, 70, 595-597.	5 <b>.</b> 6	45
80	Alzheimer's Disease: Advances in Drug Development. Journal of Alzheimer's Disease, 2018, 65, 3-13.	2.6	45
81	Structure-function analysis reveals the molecular determinants of the impaired biological function of DAX-1 mutants in AHC patients. Human Molecular Genetics, 2003, 12, 1063-1072.	2.9	44
82	A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. Alzheimer's Research and Therapy, 2014, 6, 38.	6.2	44
83	Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach. Frontiers in Neurology, 2015, 6, 181.	2.4	44
84	Hypocretin and brain $\tilde{A}\check{Z}\hat{A}^2$ -amyloid peptide interactions in cognitive disorders and narcolepsy. Frontiers in Aging Neuroscience, 2014, 6, 119.	3.4	43
85	Location of a transiently expressed glycoprotein in developing cerebellum delineating its possible ontogenetic roles. Neuroscience, 1989, 33, 111-124.	2.3	42
86	Glycoproteins and lectins in cell adhesion and cell recognition processes. The Histochemical Journal, 1992, 24, 791-804.	0.6	42
87	Comparative analysis of protein expression of three stem cell populations: Models of cytokine delivery system in vivo. International Journal of Pharmaceutics, 2013, 440, 72-82.	<b>5.</b> 2	42
88	Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations. Journal of Cell Science, 2004, 117, 5591-5597.	2.0	40
89	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30.	6.2	40
90	Cyclodextrins Inhibit Replication of Scrapie Prion Protein in Cell Culture. Journal of Virology, 2007, 81, 11195-11207.	3.4	39

#	Article	IF	Citations
91	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study. PLoS Medicine, 2020, 17, e1003289.	8.4	39
92	Prion protein suppresses perturbation of cellular copper homeostasis under oxidative conditions. Biochemical and Biophysical Research Communications, 2004, 313, 850-855.	2.1	38
93	Neural Stem Cell Model for Prion Propagation. Stem Cells, 2006, 24, 2284-2291.	3.2	37
94	SILK studies â€" capturing the turnover of proteins linked to neurodegenerative diseases. Nature Reviews Neurology, 2019, 15, 419-427.	10.1	37
95	Biological and Biochemical Characteristics of Prion Strains Conserved in Persistently Infected Cell Cultures. Journal of Virology, 2005, 79, 7104-7112.	3.4	36
96	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	2.4	36
97	From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Scientific Reports, 2016, 6, 25162.	3.3	36
98	Peripheral Blood and Salivary Biomarkers of Blood–Brain Barrier Permeability and Neuronal Damage: Clinical and Applied Concepts. Frontiers in Neurology, 2020, 11, 577312.	2.4	36
99	Effect of Congo Red on Wild-Type and Mutated Prion Proteins in Cultured Cells. Journal of Neurochemistry, 2001, 74, 222-230.	3.9	35
100	Interest of major serum protein removal for Surface-Enhanced Laser Desorption/Ionization - Time Of Flight (SELDI-TOF) proteomic blood profiling. Proteome Science, 2006, 4, 20.	1.7	35
101	Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry. Frontiers in Neuroscience, 2015, 9, 302.	2.8	34
102	New hospital disinfection processes for both conventional and prion infectious agents compatible with thermosensitive medical equipment. Journal of Hospital Infection, 2009, 72, 342-350.	2.9	33
103	Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. Alzheimer's Research and Therapy, 2020, 12, 123.	6.2	33
104	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. Nature Communications, 2021, 12, 4304.	12.8	33
105	Human S100A10 plays a crucial role in the acquisition of the endometrial receptivity phenotype. Cell Adhesion and Migration, 2016, 10, 282-298.	2.7	32
106	Association of Apolipoprotein E É>4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. JAMA Neurology, 2021, 78, 937.	9.0	32
107	Quantitative detection of amyloid- $\hat{l}^2$ peptides by mass spectrometry: state of the art and clinical applications. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1483-93.	2.3	30
108	Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 467-475.	1.9	30

7

#	Article	IF	CITATIONS
109	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1206-1214.	1.9	30
110	Cellular processing of normal and mutant mammalian prion proteins. Neurobiology of Aging, 1994, 15, S87-S88.	3.1	29
111	Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?. Clinica Chimica Acta, 2017, 467, 51-58.	1.1	29
112	Cell Culture Models of Transmissible Spongiform Encephalopathies. Biochemical and Biophysical Research Communications, 2001, 289, 311-316.	2.1	28
113	Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome. Multiple Sclerosis Journal, 2019, 25, 669-677.	3.0	28
114	Impact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: a multicenter, randomized, single-blinded trial. Critical Care, 2021, 25, 62.	5.8	28
115	Prion Replication Occurs in Endogenous Adult Neural Stem Cells and Alters Their Neuronal Fate: Involvement of Endogenous Neural Stem Cells in Prion Diseases. PLoS Pathogens, 2013, 9, e1003485.	4.7	27
116	Recombinant Human Prion Protein Inhibits Prion Propagation in vitro. Scientific Reports, 2013, 3, 2911.	3.3	27
117	Diagnosis of Methionine/Valine Variant Creutzfeldt-Jakob Disease by Protein Misfolding Cyclic Amplification. Emerging Infectious Diseases, 2018, 24, 1364-1366.	4.3	27
118	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.8	26
119	Antibodies to cerebellar soluble lectin CSL in multiple sclerosis. Lancet, The, 1990, 335, 1482-1484.	13.7	25
120	Effect of Amphotericin B on Wild-Type and Mutated Prion Proteins in Cultured Cells. Journal of Neurochemistry, 2001, 74, 754-762.	3.9	25
121	Isolation of Exosomes and Microvesicles from Cell Culture Systems to Study Prion Transmission. Methods in Molecular Biology, 2017, 1545, 153-176.	0.9	25
122	Association between serum hepcidin level and restless legs syndrome. Movement Disorders, 2018, 33, 618-627.	3.9	25
123	Performance evaluation of human cytokines profiles obtained by various multiplexed-based technologies underlines a need for standardization. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1385-93.	2.3	24
124	Relationship between genome and epigenome - challenges and requirements for future research. BMC Genomics, 2014, 15, 487.	2.8	24
125	Rapid and Highly Sensitive Detection of Variant Creutzfeldt - Jakob Disease Abnormal Prion Protein on Steel Surfaces by Protein Misfolding Cyclic Amplification: Application to Prion Decontamination Studies. PLoS ONE, 2016, 11, e0146833.	2.5	24
126	Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand?. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 99-113.	6.1	24

#	Article	IF	CITATIONS
127	The truncated 23-230 form of the prion protein localizes to the nuclei of inducible cell lines independently of its nuclear localization signals and is not cytotoxic. Molecular and Cellular Neurosciences, 2006, 32, 315-323.	2.2	23
128	Stem Cell Therapy Extends Incubation and Survival Time in Prion-Infected Mice in a Time Window–Dependant Manner. Journal of Infectious Diseases, 2011, 204, 1038-1045.	4.0	23
129	Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation. Journal of Alzheimer's Disease, 2016, 50, 759-764.	2.6	23
130	Glycosylation of prions and its effects on protein conformation relevant to amino acid mutations. Journal of Molecular Graphics and Modelling, 2000, 18, 126-134.	2.4	22
131	A Novel Copper–Hydrogen Peroxide Formulation for Prion Decontamination. Journal of Infectious Diseases, 2006, 194, 865-869.	4.0	22
132	Absolute quantification of 35 plasma biomarkers in human saliva using targeted MS. Bioanalysis, 2016, 8, 43-53.	1.5	22
133	Proteomics of primary mesenchymal stem cells. Regenerative Medicine, 2006, 1, 511-517.	1.7	21
134	Prions Impair Bioaminergic Functions through Serotonin- or Catecholamine-derived Neurotoxins in Neuronal Cells. Journal of Biological Chemistry, 2008, 283, 23782-23790.	3.4	21
135	Hepcidin and ferritin levels in restless legs syndrome: a case–control study. Scientific Reports, 2020, 10, 11914.	3.3	21
136	Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study. Alzheimer's and Dementia, 2022, 18, 2537-2550.	0.8	21
137	Sample Pooling and Inflammation Linked to the False Selection of Biomarkers for Neurodegenerative Diseases in Top–Down Proteomics: A Pilot Study. Frontiers in Molecular Neuroscience, 2018, 11, 477.	2.9	20
138	Correlation between Bioassay and Protein Misfolding Cyclic Amplification for Variant Creutzfeldt-Jakob Disease Decontamination Studies. MSphere, 2020, 5, .	2.9	20
139	Cellular pathogenesis in prion diseases. Veterinary Research, 2008, 39, 44.	3.0	20
140	The prognostic value of theÂTau protein serum level in metastatic breast cancer patients and its correlation with brain metastases. BMC Cancer, 2019, 19, 110.	2.6	20
141	Trafficking of the cellular isoform of the prion protein. Biomedicine and Pharmacotherapy, 1999, 53, 39-46.	5.6	19
142	Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?. EuPA Open Proteomics, 2014, 3, 60-67.	2.5	19
143	Development of new quantitative mass spectrometry and semi-automatic isofocusing methods for the determination of Apolipoprotein E typing. Clinica Chimica Acta, 2016, 454, 33-38.	1.1	19
144	Clinical perspectives of dried blood spot protein quantification using mass spectrometry methods. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 173-184.	6.1	19

#	Article	IF	Citations
145	A Clinico-Radiological Study of Cerebral Amyloid Angiopathy-Related Inflammation. Cerebrovascular Diseases, 2019, 48, 38-44.	1.7	19
146	Lesion-induced re-expression of neonatal recognition molecules in adult rat cerebellum. Brain Research Bulletin, 1993, 30, 515-521.	3.0	18
147	Prion-like protein Doppel expression is not modified in scrapie-infected cells and in the brains of patients with Creutzfeldt-Jakob disease. FEBS Letters, 2003, 536, 61-65.	2.8	18
148	Oligomeric-Induced Activity by Thienyl Pyrimidine Compounds Traps Prion Infectivity. Journal of Neuroscience, 2011, 31, 14882-14892.	3.6	18
149	Operative definition of active and healthy ageing (AHA): Meeting report. Montpellier October 20–21, 2014. European Geriatric Medicine, 2015, 6, 196-200.	2.8	18
150	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	2.6	18
151	Reduced brain amyloid burden in elderly patients with narcolepsy type 1. Annals of Neurology, 2019, 85, 74-83.	5.3	18
152	The importance of an integrated genotype-phenotype strategy to unravel the molecular bases of titinopathies. Neuromuscular Disorders, 2020, 30, 877-887.	0.6	18
153	Hypoxemia increases blood-brain barrier permeability during extreme apnea in humans. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 1120-1135.	4.3	18
154	The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone. Alzheimer's Research and Therapy, 2022, 14, 20.	6.2	18
155	Detection of prion after decontamination procedures: comparative study of standard Western blot, filter retention and scrapie-cell assay. Journal of Hospital Infection, 2004, 57, 156-161.	2.9	17
156	Towards a routine application of Top-Down approaches for label-free discovery workflows. Journal of Proteomics, 2018, 175, 12-26.	2.4	17
157	Cerebral Amyloid Angiopathy and Cerebral Amyloid Angiopathy-Related Inflammation: Comparison of Hemorrhagic and DWI MRI Features. Journal of Alzheimer's Disease, 2018, 64, 1113-1121.	2.6	17
158	Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. Clinica Chimica Acta, 2019, 490, 98-101.	1.1	17
159	Systemic Delivery of siRNA Down Regulates Brain Prion Protein and Ameliorates Neuropathology in Prion Disorder. PLoS ONE, 2014, 9, e88797.	2.5	16
160	Editorial: Biomarkers of Alzheimer's Disease: The Present and the Future. Frontiers in Neurology, 2016, 7, 158.	2.4	16
161	Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis. Journal of Alzheimer's Disease, 2016, 54, 1291-1295.	2.6	16
162	Impurity determination for hepcidin by liquid chromatography-high resolution and ion mobility mass spectrometry for the value assignment of candidate primary calibrators. Analytical and Bioanalytical Chemistry, 2017, 409, 2559-2567.	3.7	16

#	Article	IF	CITATIONS
163	Presence of anti-CSL antibodies in the cerebrospinal fluid of patients: A sensitive and specific test in the diagnosis of multiple sclerosis. Journal of Neuroimmunology, 1994, 52, 175-182.	2.3	14
164	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. Neurobiology of Disease, 2013, 54, 486-491.	4.4	14
165	Comparison of HbA1c detection in whole blood and dried blood spots using an automated ion-exchange HPLC system. Bioanalysis, 2017, 9, 427-434.	1.5	14
166	Cerebrospinal Fluid, MRI, and Florbetaben-PET in Cerebral Amyloid Angiopathy-Related Inflammation. Journal of Alzheimer's Disease, 2018, 61, 1107-1117.	2.6	14
167	The potential impact of salivary peptides in periodontitis. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 479-492.	6.1	14
168	Cytokines as new biomarkers of skin wound vitality. International Journal of Legal Medicine, 2021, 135, 2537-2545.	2.2	14
169	Quantifying RNA modifications by mass spectrometry: a novel source of biomarkers in oncology. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 1-18.	6.1	14
170	An endogenous lectin and its glycoprotein ligands are triggering basal and axon-induced Schwann cell proliferation. Glycobiology, 1995, 5, 371-383.	2.5	13
171	A wild-type prion protein does not acquire properties of the scrapie isoform when coexpressed with a mutant prion protein in cultured cells. Molecular Brain Research, 1997, 52, 139-145.	2.3	13
172	Proteomic consequences of expression and pathological conversion of the prion protein in inducible neuroblastoma N2a cells. Prion, 2010, 4, 292-301.	1.8	13
173	Lateâ€onset behavioral variant of frontotemporal lobar degenerationÂversus Alzheimer's disease: Interest of cerebrospinal fluidÂbiomarkerÂratios. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 371-379.	2.4	13
174	Data from a targeted proteomics approach to discover biomarkers in saliva for the clinical diagnosis of periodontitis. Data in Brief, 2018, 18, 294-299.	1.0	13
175	Biomarkers of Alzheimer's disease: The present and the future. Revue Neurologique, 2013, 169, 719-723.	1.5	12
176	Quantification of hepcidin-25 in human cerebrospinal fluid using LC–MS/MS. Bioanalysis, 2017, 9, 337-347.	1.5	12
177	Assessing a multiplex-targeted proteomics approach for the clinical diagnosis of periodontitis using saliva samples. Bioanalysis, 2018, 10, 35-45.	1.5	12
178	Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches. Data in Brief, 2018, 18, 1013-1021.	1.0	12
179	What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?. Bioanalysis, 2018, 10, 723-735.	1.5	12
180	Deconstructing Alzheimer's Disease: How to Bridge the Gap between Experimental Models and the Human Pathology?. International Journal of Molecular Sciences, 2021, 22, 8769.	4.1	12

#	Article	IF	CITATIONS
181	Genetic heterogeneity versus molecular analysis of prion susceptibility in neuroblasma N2a sublines. Archives of Virology, 2008, 153, 1693-1702.	2.1	11
182	A new genetic algorithm in proteomics: Feature selection for SELDI-TOF data. Computational Statistics and Data Analysis, 2008, 52, 4380-4394.	1.2	11
183	Autoantibody profiling on high-density protein microarrays for biomarker discovery in the cerebrospinal fluid. Journal of Immunological Methods, 2008, 338, 75-78.	1.4	11
184	Production of a monoclonal antibody, against human $\hat{l}_{\pm}$ -synuclein, in a subpopulation of C57BL/6J mice, presenting a deletion of the $\hat{l}_{\pm}$ -synuclein locus. Journal of Neuroscience Methods, 2010, 192, 268-276.	2.5	11
185	Prion diseases and adult neurogenesis: How do prions counteract the brain's endogenous repair machinery?. Prion, 2014, 8, 240-246.	1.8	11
186	Initial Memory Deficit Profiles in Patients with a Cerebrospinal Fluid Alzheimer's Disease Signature. Journal of Alzheimer's Disease, 2014, 41, 1109-1116.	2.6	11
187	NFL strongly correlates with TNF-R1 in the plasma of AD patients, but not with cognitive decline. Scientific Reports, 2021, 11, 10283.	3.3	11
188	Cerebrospinal fluid anti-cerebellar soluble lectin antibodies in human immunodeficiency virus type 1 infection. Journal of Neuroimmunology, $1992$ , $36$ , $245$ - $249$ .	2.3	10
189	Endogenous Lectin Cerebellar Soluble Lectin Involved in Myelination Is Absent from Nonmyelinating Schwann Cells. Journal of Neurochemistry, 1992, 58, 1768-1772.	3.9	10
190	BSE infection of the small short-lived primate Microcebus murinus. Comptes Rendus - Biologies, 2002, 325, 67-74.	0.2	10
191	Stable Isotope Labeling by Amino acid (i>in Vivo (i) (SILAV): a new method to explore protein metabolism. Rapid Communications in Mass Spectrometry, 2015, 29, 1917-1925.	1.5	10
192	Multicenter Analytical Validation of A $\hat{I}^2$ 40 Immunoassays. Frontiers in Neurology, 2017, 8, 310.	2.4	10
193	Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1–42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2018, 10, 297.	3.4	10
194	Sensitive protein misfolding cyclic amplification of sporadic Creutzfeldt–Jakob disease prions is strongly seed and substrate dependent. Scientific Reports, 2021, 11, 4058.	3.3	10
195	Differential expression of an endogenous mannose-binding protein R1 during muscle development and regeneration delineating its role in myoblast fusion. Glycobiology, 1994, 4, 23-38.	2.5	9
196	Impact of iron deficiency diagnosis using hepcidin mass spectrometry dosage methods on hospital stay and costs after a prolonged ICU stay: Study protocol for a multicentre, randomised, single-blinded medico-economic trial. Anaesthesia, Critical Care & Damp; Pain Medicine, 2017, 36, 391-396.	1.4	9
197	Regulatory context and validation of assays for clinical mass spectrometry proteomics (cMSP) methods. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 346-358.	6.1	9
198	Lithium as a disease-modifying agent for prion diseases. Translational Psychiatry, 2018, 8, 163.	4.8	9

#	Article	IF	Citations
199	Dental stem cells as a promising source for cell therapies in neurological diseases. Critical Reviews in Clinical Laboratory Sciences, 2019, 56, 170-181.	6.1	9
200	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 74, 903-911.	2.6	9
201	Gravitational Transitions Increase Posterior Cerebral Perfusion and Systemic Oxidative-nitrosative Stress: Implications for Neurovascular Unit Integrity. Neuroscience, 2020, 441, 142-160.	2.3	9
202	Neurite outgrowth of neurons of rat dorsal root ganglia induced by new neurotrophic substances with guanidine group. Neuroscience Letters, 1993, 152, 57-60.	2.1	8
203	Prion Propagation in Cell Culture. , 2005, 299, 227-234.		8
204	Elevated plasma cysteinylglycine levels caused by cilastatin-associated antibiotic treatment. Clinical Chemistry and Laboratory Medicine, 2005, 43, 332-4.	2.3	8
205	The Role of the Prion Protein in the Molecular Basis for Synaptic Plasticity and Nervous System Development. Journal of Molecular Neuroscience, 2008, 34, 9-15.	2.3	8
206	Development and validation of dried matrix spot sampling for the quantitative determination of amyloid $\hat{l}^2$ peptides in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2014, 52, 649-55.	2.3	8
207	Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?. Alzheimer's and Dementia, 2015, 11, 1125-1126.	0.8	8
208	Biochemical markers of time since death in cerebrospinal fluid: A first step towards"Forensomics― Critical Reviews in Clinical Laboratory Sciences, 2019, 56, 274-286.	6.1	8
209	Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer. International Journal of Cancer, 2021, 149, 1605-1618.	5.1	8
210	MACVIA-LR (FIGHTING CHRONIC DISEASES FOR ACTIVE AND HEALTHY AGEING IN LANGUEDOC-ROUSSILLON): A SUCCESS STORY OF THE EUROPEAN INNOVATION PARTNERSHIP ON ACTIVE AND HEALTHY AGEING. Journal of Frailty & Damp; Aging, the, 2016, 5, 1-9.	1.3	8
211	Cerebellar Lectins. International Review of Cytology, 1992, 135, 123-154.	6.2	7
212	From "Clinical Proteomics―to "Clinical Chemistry Proteomics― considerations using quantitative mass-spectrometry as a model approach. Clinical Chemistry and Laboratory Medicine, 2012, 50, 235-42.	2.3	7
213	Interlaboratory validation of cerebrospinal fluid αâ€synuclein quantification in the diagnosis of sporadic Creutzfeldtâ€Jakob disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 461-470.	2.4	7
214	Generation of induced pluripotent stem cells (IRMBi001-A) from an Alzheimer's disease patient carrying a G217D mutation in the PSEN1 gene. Stem Cell Research, 2019, 34, 101381.	0.7	7
215	Variation of human salivary alpha-amylase proteoforms in three stimulation models. Clinical Oral Investigations, 2020, 24, 475-486.	3.0	7
216	Tau protein in cerebrospinal fluid: a novel biomarker of the time of death?. International Journal of Legal Medicine, 2021, 135, 2081-2089.	2.2	7

#	Article	IF	CITATIONS
217	Concussion history in rugby union players is associated with depressed cerebrovascular reactivity and cognition. Scandinavian Journal of Medicine and Science in Sports, 2021, 31, 2291-2299.	2.9	7
218	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. Journal of Neural Transmission, 2022, 129, 231-237.	2.8	7
219	Heat Shock Affects Trafficking of DAX-1 by Inducing Its Rapid and Reversible Cytoplasmic Localization. Endocrine, 2005, 28, 137-144.	2.2	6
220	An innovative biologic recycling process of leukoreduction filters to produce active human antimicrobial peptides. Transfusion, 2014, 54, 1332-1339.	1.6	6
221	Nano-flow vs standard-flow: Which is the more suitable LC/MS method for quantifying hepcidin-25 in human serum in routine clinical settings?. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1086, 110-117.	2.3	6
222	In Vivo Large-Scale Mapping of Protein Turnover in Human Cerebrospinal Fluid. Analytical Chemistry, 2019, 91, 15500-15508.	6.5	6
223	Analytical comparison of ELISA and mass spectrometry for quantification of serum hepcidin in critically ill patients. Bioanalysis, 2021, 13, 1029-1035.	1.5	6
224	Comparison of cerebrospinal fluid tau, ptau(181), synuclein, and 14-3-3 for the detection of Creutzfeldt–Jakob disease in clinical practice. Journal of Neural Transmission, 2022, 129, 133-139.	2.8	6
225	Impact of biological matrix on inflammatory protein biomarker quantification based on targeted mass spectrometry. Bioanalysis, 2018, 10, 1383-1399.	1.5	5
226	Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers. Current Alzheimer Research, 2018, 15, 691-700.	1.4	5
227	Determination of plasma amino acids by fluorescent derivatization and reversed-phase liquid chromatographic separation. Clinical Laboratory, 2004, 50, 153-8.	0.5	5
228	Deciphering Black Extrinsic Tooth Stain Composition in Children Using Metaproteomics. ACS Omega, 2022, 7, 8258-8267.	<b>3.</b> 5	5
229	HEPES inhibits the conversion of prion protein in cell culture. Journal of General Virology, 2011, 92, 1244-1250.	2.9	4
230	Proteomic profile of cerebrospinal fluid in patients with multiple sclerosis using two dimensional gel electrophoresis. British Journal of Biomedical Science, 2016, 73, 143-146.	1.3	4
231	Cell-based therapy against prion diseases. Current Opinion in Pharmacology, 2019, 44, 8-14.	3.5	4
232	Efficient extraction of intact HSA- $\hat{Al^2}$ peptide complexes from sera: Toward albuminome biomarker identification. Talanta, 2020, 216, 121002.	5 <b>.</b> 5	4
233	Prion Protein Expression and Processing in Human Mononuclear Cells: The Impact of the Codon 129 Prion Gene Polymorphism. PLoS ONE, 2009, 4, e5796.	2.5	4
234	Le rÃ1e de la protéine du prion dans les encéphalopathies spongiformes transmissibles humaines Medecine/Sciences, 1996, 12, 949.	0.2	4

#	Article	IF	CITATIONS
235	Added value of hepcidin quantification for the diagnosis and follow-up of anemia-related diseases. Annales De Biologie Clinique, 2017, 75, 9-18.	0.1	3
236	Looking for new biomarkers of skin wound vitality with a cytokine-based multiplex assay: preliminary study. Annales De Biologie Clinique, 2017, 75, 53-60.	0.1	3
237	Two Dimensional Gel Electrophoresis Analysis of Mesenchymal Stem Cells. Methods in Molecular Biology, 2011, 698, 431-442.	0.9	3
238	Brain Lectins:Structure and Function Trends in Glycoscience and Glycotechnology, 1992, 4, 415-426.	0.1	3
239	Ex Vivo Transmission of Mouse-Adapted Prion Strains to N2a and GT1-7 Cell Lines. , 0, , 679-686.		2
240	From stem cells to prion signalling. Comptes Rendus - Biologies, 2002, 325, 9-15.	0.2	2
241	La Protéine du Prion. Société De Biologie Journal, 2002, 196, 309-312.	0.3	2
242	MALDIâ€₹OF IPâ€MS quantification of plasma amyloid peptides in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e047112.	0.8	2
243	Quiescin-sulfhydryl oxidase inhibits prion formation in vitro. Aging, 2016, 8, 3419-3429.	3.1	2
244	Comparison of Hydrophobic, Lipophilic and Immunodepletion Pre- Fractionation Methods for Label-Free LC-MS/MS Identification of Biomarkers in Human Cerebrospinal Fluid. Journal of Proteomics and Bioinformatics, 0, s5, .	0.4	2
245	Comparison between surface and bead-based MALDI profiling technologies using a single bioinformatics algorithm. Clinical Proteomics, 2006, 2, 145-152.	2.1	1
246	Analytical challenges related to the use of biomarker ratios for the biological diagnosis of Alzheimer's disease. Clinical Chemistry and Laboratory Medicine, 2015, 53, e175-7.	2.3	1
247	What is the potential of dried matrix spot sampling for cerebrospinal fluid analysis? Bioanalysis, 2015, 7, 2849-2851.	1.5	1
248	O1â€05â€04: PROFILING OF INTACT PROTEINS IN THE CSF OF ALZHEIMER'S DISEASE PATIENTS USING TOP D CLINICAL PROTEOMICS (TDCP): A NEW APPROACH GIVING ACCESS TO ISOFORM SPECIFIC INFORMATION OF NEURODEGENERATIVE BIOMARKERS. Alzheimer's and Dementia, 2016, 12, P183.	OOWN 0.8	1
249	Characterizing Deep White Matter Hyperintensities in Patients with Symptomatic Isolated Cortical Superficial Siderosis. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 465-469.	1.6	1
250	Editorial: Proteomics as a Tool for Biomarker and Drug Target Discovery: Improving the Diagnosis and Treatment of Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2020, 12, 232.	3.4	1
251	From Chemical Drug to Immunotherapy: New Approaches for the Treatment of Prion Diseases. Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents, 2003, 3, 199-205.	0.2	1
252	Transcriptomic and proteomic analyses of human endometrial receptivity under natural cycle. Fertility and Sterility, 2012, 98, S226.	1.0	0

#	Article	IF	Citations
253	O1-09-02: DETECTION AND QUANTIFICATION OF THE TAU PROTEIN AND ITS ISOFORMS IN THE CSF OF ALZHEIMER'S DISEASE PATIENTS USING MASS SPECTROMETRY. , 2014, 10, P147-P147.		O
254	O5-05-04: Large scale proteomics exploration of human cerebrospinal fluid (CSF) in Alzheimer's disease patients using stable isotope labeling amino acid in vivo (SILAV)., 2015, 11, P326-P326.		0
255	Amyloid imaging by 18F-florbetaben PET in a patient with isolated microbleeds and leukoencephalopathy. Acta Neurologica Belgica, 2016, 116, 623-625.	1.1	O
256	Hepcidin: immunoanalytic characteristics. Annales De Biologie Clinique, 2018, 76, 705-715.	0.1	0
257	Stable Isotope Labeling Kinetics in CNS Translational Medicine: Introduction to SILK Technology. Handbook of Behavioral Neuroscience, 2019, 29, 173-190.	0.7	O
258	Intact Protein Analysis by LC-MS for Characterizing Biomarkers in Cerebrospinal Fluid. Methods in Molecular Biology, 2019, 1959, 163-172.	0.9	0
259	Immunoassay and Mass Spectrometry Methods for Tau Protein Quantification in the Cerebrospinal Fluid. Neuromethods, 2021, , 71-85.	0.3	O
260	Familial Prion Diseases Modeled in Cell Culture. , 1998, , 87-98.		0
261	Reform of the outside nomenclature biomedical tests in France: a two year review. Annales De Biologie Clinique, 2017, 75, 365-365.	0.1	O
262	Title is missing!. , 2020, 17, e1003289.		0
263	Title is missing!. , 2020, 17, e1003289.		O
264	Title is missing!. , 2020, 17, e1003289.		0
265	Title is missing!. , 2020, 17, e1003289.		O
266	Title is missing!. , 2020, 17, e1003289.		0
267	Title is missing!. , 2020, 17, e1003289.		0
268	Title is missing!. , 2020, 17, e1003289.		0